Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 84 publications.

Vila Guilera J, Abellan A, Garcia de Albeniz X, Houghton K. External control arm studies in marketing authorisation applications submitted to the European Medicines Agency: a review of study design features and methods. Presented at the Drug Information Association (DIA) Europe 2025; March 18, 2025. Basel, Switzerland.

Silver SM, Houghton K, Hitchens A, Ansquer VD, Ciepielewska M. Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria. J Dermatol. 2025 Mar;52(3):416-22. doi: 10.1111/1346-8138.17607

Krishnamurthy P, Houghton K, Lorenz N, Williams P, Currie L, Vigil CE, Ziba N, Bello F, Sieluk J, Strocchia M, Li Y, Kapp-Schwoerer S. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 7, 2024. San Diego, CA.

Neofytos D, Pagliuca A, Houghton K, Broughton E, de Figueiredo Valente MLN, Jiang L, Enoch DA, Gruener B, Herbrecht R, Lahmer T, Lortholary O, Melenotte C, De Rosa FG, Garcia-Vidal C, Jimenez M, Fernandez M, Cornely O. Effectiveness, safety, and patterns of real-world isavuconazole use in Europe (2015-2019). Infect Dis Ther. 2024 Dec;13(12):2527-43. doi: 10.1007/s40121-024-01064-4

Dave RH, Crayton H, Miravalle A, Tai MH, Wyse K, Houghton K, Hitchens A, Berkovich R. COVID-19 vaccination response in patients with multiple sclerosis treated with ofatumumab in the United States: a medical record review. Neurol Ther. 2024 Dec;13(6):1737-45. doi: 10.1007/s40120-024-00671-0

Tilman Steinmetz H, Ertel F, Brinkmann B, Houghton K, Nham T, Flossmann C. Treatment goals and decision-making criteria for second- and third-line therapy for multiple myeloma in Germany. Poster presented at the European Hematology Association (EHA) 2024 Hybrid Congress; June 13, 2024. Madrid, Spain.

Shinde S, Thieu VT, Kwan AYM, Houghton K, Meyers J, Schapiro D. Impact of weight change on glycemic control and metabolic parameters in T2D: a retrospective us study based on real-world data. Diabetes Ther. 2024 Feb;15(2):409-26. doi: 10.1007/s13300-023-01511-4.

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772

Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S119. doi: 10.1016/j.jval.2023.09.772

Houghton K, Nangia A, Hawe E. Use of external control arms (ECAs) in marketing applications submitted to European medicines agency (EMA): a targeted review. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S404. doi: 10.1016/j.jval.2023.09.2119

Nangia A, Houghton K, Hawe E. Use of external control arms in pharmaceutical submissions to the national institute for health and care excellence for technology appraisals: a targeted review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S416. doi: 10.1016/j.jval.2023.09.2180

Castro E, Schlack K, Niyazov A, Houghton K, Kirker M, Derrien Ansquer V, Bello F, Jones RJ. Impact of treatment (tx) intensification on tx patterns and outcomes in the real world (rw) among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in Europe. Poster presented at the 15th European Multidisciplinary Congress on Urological Cancers; November 2, 2023. Marseille, France.

Houghton K, Hitchens A, Ciepielewska M. Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S155. doi: 10.1016/j.jval.2023.03.2501

Sung A, Houghton K, Cornely OA, Neofytos D, Pagliuca A, Capparella MR, Aguado J, Jimenez M, Gheorghe M. Effectiveness, safety, and patterns of real-world isavuconazole use—a retrospective medical record review study of patients with invasive aspergillosis. Poster presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023; April 15, 2023. Copenhagen, Denmark.

Fliser D, Lorenzo MM, Houghton K, Ainsworth C, Blogg M, Gonzalez de Antona Sanchez E, Portles J. Real-life anemia management among patients with non-dialysis-dependent chronic kidney disease in three European countries. Int J Nephrol Renovasc Dis. 2023 Apr 13;16:115-29. doi: 10.2147/IJNRD.S401598

DePree B, Houghton K, DiBenedetti DB, Shiozawa A, King DD, Kim J, Mancuso S. Practice patterns and perspectives regarding treatment for symptoms of menopause: qualitative interviews with US health care providers. Menopause. 2023 Feb;30(2):128-35. doi: 10.1097/GME.0000000000002096

DePree B, Houghton K, Shiozawa A, Esterberg E, King D, Kim J, Mancuso S. Treatment and resource utilization for menopausal symptoms in the United States: a retrospective review of real-world evidence from US electronic health records. Menopause. 2023 Jan 1;30(1):70-9. doi: 10.1097/GME.0000000000002095

Sluga-O'Callaghan M, Derrien Ansquer V, Frugier G, Houghton K. Evaluation of national approvals and data-collection durations in retrospective noninterventional medical record review studies conducted in the United States, Canada, Europe, and Asia. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S488-9. doi: 10.1016/j.jval.2022.09.2424

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Published Erratum - Correction to: Staging disease severity using the Alzheimer's Disease Composite Score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Jun;11(2):915-27. doi: 10.1007/s40120-022-00340-0

Ciepielewska M, Hagan M, Houghton K, Hitchens A, Ansquer V, Silver SM. Real-world treatment patterns and healthcare resource utilization among patients diagnosed with erythropoietic protoporphyria and x-linked protoporphyria: results from a US electronic medical records study. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).

DePree B, Houghton K, Shiozawa A, Esterberg E, Kim J, Mancuso S. Real-world treatment for menopausal symptoms in the US by practitioner type. Poster presented at the American College of Obstetricians and Gynecologists (ACOG) 2022 Annual Meeting; May 6, 2022. San Diego, CA.

Tahami Monfared AA, Houghton K, Zhang Q, Mauskopf J, Alzheimer’s Disease Neuroimaging Initiative. Staging disease severity using the Alzheimer's disease composite score (ADCOMS): a retrospective data analysis. Neurol Ther. 2022 Mar;11(1):413-34. doi: 10.1007/s40120-022-00326-y

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment structures and resource use in non-dialysis-dependent CKD patients (NDD-CKD) with renal anemia: a retrospective analysis. Poster presented at the Kongress fur NepHROlogie 2021 13th Annual Meeting; September 23, 2021.

DePree B, Houghton K, Shiozawa A, Esterberg E, King D, Kim J, Mancuso S. Real-world treatment and resource utilization for menopausal symptoms in the United States. Presented at the 2021 North American Menopause Society (NAMS) Annual Meeting; September 23, 2021.

Houghton K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of Secukinumab. Dermatol Ther. 2021 Aug;11(4):1373-84. doi: 10.1007/s13555-021-00564-2

Fliser D, Portoles J, Houghton K, Ainsworth C, Blogg M, Lorenzo MM. Treatment of anaemia with erythropoiesis-stimulating agents (ESAs) and concomitant therapies among patients with non-dialysis dependent chronic kidney disease (NDD-CKD) in Germany, Spain and the UK: a retrospective chart review. Poster presented at the 2021 58th ERA-EDTA Virtual Congress; June 5, 2021.

Ciarametaro M, Houghton K, Wamble D, Dubois R. The dollar or disease burden: caps on health care spending may save money, but at what “cost” to patients? Value Health. 2021 Mar;24(3):388-96. doi: 10.1016/j.jval.2020.10.024v

Stull K, Patil D, Gomez B, Feldman SR. Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase III clinical trials. Poster presented at the 2020 Virtual 29th European Academy of Dermatology and Venerology Congress; October 28, 2020.

Tahami Monfared AA, Stull K, Zhang Q. Staging early Alzheimer's disease using the Alzheimer's Disease Composite Score (ADCOMS). Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 2019. San Diego, CA.

Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4

Houghton K, Dimopoulos M, Lin PL, Guillonneau S, Bury S, Attal M, Richardson PG, Delforge M. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with isatuximab plus pomalidomide and dexamethasone: Icaria-MM study. Poster presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):1850. doi: 10.1182/blood-2019-128220

Houghton K, Stull D, Germino B. A novel analytic modeling approach for linking real-world and clinical trial data. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 22, 2019. New Orleans, LA.

Houghton K, Ainsworth C, Stull D, Haberland C, Filonenko A, Seitz C, Gerlinger C. Exploring variability in patient-reported pain and treatment efficacy in patients with endometriosis. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.

Williams V, Stull D, Houghton K, Williams N, Teynor M. Minimal clinically important differences of the expanded hammersmith functional motor scale in later-onset spinal muscular atrophy: results from the Phase 3 CHERISH trial. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Spec Pharm. 2019 Mar; 25(3-a Suppl):S54.

Stull D, Williams V, Houghton K, Williams N, Teynor M. Minimal clinically important differences in motor function in patients with infantile-onset spinal muscular atrophy: results from the Phase 3 ENDEAR trial. Poster presented at the 2019 AMCP Managed Care & Specialty Pharmacy Annual Meeting; March 25, 2019. San Diego, CA. [abstract] J Manag Care Spec Pharm. 2019 Mar; 25(3-a Suppl):S55.

Wamble DE, Ciarametaro M, Houghton K, Ajmera M, Dubois RW. What's been the bang for the buck? Cost-effectiveness of health care spending across selected conditions in the US. Health Aff (Millwood). 2019 Jan;38(1):68-75. doi: 10.1377/hlthaff.2018.05158.

Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1

Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018 Jun;178(6):1297-307. doi: 10.1111/bjd.16366

Maurer M, Houghton K, Berroa F, Ensina LF, Guillet G, Labrador M, Gimenez-Arnau AM, Marsland A, Rossi O, Velasco M, Chapman-Rothe N. Angioedema with and without wheals in patients with chronic spontaneous urticaria: findings from the worldwide prospective observational aware study. Presented at the EAACI Congress 2018; May 27, 2018. Munich, Germany.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and presence of angioedema among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.

Maurer M, Houghton K, Guillet G, Kasujee I, Labrador M, Marsland M, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Quality of life and disease control among patients with chronic urticaria in Europe: longitudinal findings from the worldwide prospective observational AWARE study. Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.

Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Chronic inducible urticaria (CIndU) in Europe, Central America, and South America: findings from visit 1 of the worldwide AWARE Study. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.

Maurer M, Guillet G, Houghton K, Kasujee I, Labrador M, Marsland A, McBride D, Rossi O, Stull DE, Valesco M, Chapman-Rothe N. Treatment of patients with chronic urticaria in Europe: findings from visit 1 of the worldwide prospective observational AWARE study. Poster presented at the EAACI Congress 2017; June 19, 2017. Helsinki, Finland.

Maurer M, Berroa F, Castronuovo A, Ensina LF, Guillet G, Kasujee I, Houghton K, Labrador M, Marsland A, McBride D, Rossi O, Valesco M, Stull DE, Chapman-Rothe N. Healthcare resource utilisation due to chronic urticaria in Europe, South America, and Central America: findings from visit 1 of the worldwide AWARE study. Poster presented at the EAACI Congress 2017; June 18, 2017. Helsinki, Finland.

Boye ME, Houghton K, Stull DE, Ainsworth C, Price GL. Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease: MONARCH 1. Poster presented at the 2017 ASCO Annual Meeting; June 4, 2017. Chicago, IL. [abstract] J Clin Oncol. 2017 Jun; 35(2017).

Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.

Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.

Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.

Puig L, Griffiths CE, Zhou Y, Gilloteau I, Guana A, Houghton K, Stull DE. Differential effects of secukinumab vs. ustekinumab for treatment of moderate to severe psoriasis on work productivity and activity impairment: a structural equation modelling approach using the CLEAR 52-week study. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A161.

Stull DE, Houghton K, Ainsworth C, Brown J, Bowman L, Boye ME. "Causal cascade" among outcomes in non-small cell lung cancer: assessing the direct and indirect effects of symptoms on health-related quality of life (HRQL) outcomes. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A748.